This article has been updated with comments and additional information from the firm's conference call.

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its fourth-quarter revenues increased 30 percent on strong instrument and reagent growth.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $49.2 million for the three-month period ended Dec. 31, compared to $37.8 million for the fourth quarter of 2008. The company easily beat analysts' consensus estimate of $45.4 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.